KOL Perspectives: Perception of mirikizumab in moderate-to-severe UC

Market: Pharmaceuticals and Healthcare

Global, 32 pages report, published by GlobalData

Report ThumbnailAugust-2018
KOL Perspectives: Perception of mirikizumab in moderate-to-severe UC

Summary

This KOL Insight briefing focuses on KOLs views of mirikizumab in moderate-to-severe UC.

Questions topics -
- Perception of Phase II mirikizumab induction data in UC
- Perception of mirikizumab’s Phase III study in UC
- Future expectations of mirikizumab in UC
- Future expectations for mirikizumab in Crohn’s disease

Key Highlights

- All but one KOL noted that 200mg was the optimal dose for mirikizumab in UC, while

Read More
  • Table of Contents
  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications
  • Appendix
Read More

Please select a license type

Share

Related Products

GlobalDataKOL Perspectives: Perception of mirikizumab in moderate-to-severe UCProduct ThumbnailKOL Perspectives: Perception of mirikizumab in moderate-to-severe UC, Industry ReportProduct #: 1194151
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2019 Global Market Analyst. All Rights Reserved